BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 13, 2025
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 17, 2010
View Archived Issues
NPS Pharmaceuticals Rakes in $38.6M to Advance Pipeline
Read More
Actis Biologics to Raise $380M, for Malaysia, India Ventures
Read More
FDA Panel Backs Alkermes Drug Vivitrol for Opioid Dependence
Read More
Stock Movers
Read More
Forest to Pay $313M to Settle Unapproved Drug Charges
Read More
Clinic Roundup
Read More
Other News To Note
Read More
FDA Panel Rejects Arena's Weight Loss Drug Lorcaserin
ADELPHI, Md. – An FDA panel Thursday said the potential risks of tumors, psychiatric effects and heart problems outweighed any benefits of weight loss with Arena Pharmaceuticals Inc.'s Lorquess (lorcaserin). (BioWorld Today)
Read More
Size Matters: Virtual Firms Run Lean, Struggle for Exits
Read More
